Intra-myometrial Vasopressin During Cesarean Section in Placenta Previa
Status:
Completed
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
Placenta previa can have serious adverse consequences for the mother, including an increased
risk of maternal mobility, antenatal and intrapartum hemorrhage, and the mother may,
therefore, require a blood transfusion or even an emergency hysterectomy. Although it is a
relatively rare condition with an overall incidence of 0.28-2.0% of all deliveries, it has
been suggested that the incidence of placenta previa is increasing. Many gynecological
surgeons use a local injection of vasopressin, which is a known peripheral vasoconstrictor,
at the time of laparoscopic myomectomy to decrease blood loss. In addition, the useful role
for local infiltration of vasopressin to arrest hemorrhage from the placental bed has been
demonstrated in several obstetrical case reports. The vasopressin V1α receptor has been
demonstrated to be present in the myometrium of both non-pregnant and pregnant women and
contributes to myometrial contraction. Therefore, the investigators evaluated the effect of
local injection of vasopressin on the blood loss and secondary impact on complications during
cesarean section in cases of placenta previa.